irinotecan has been researched along with mk-8776 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Chang, LJ; Eastman, A | 1 |
2 other study(ies) available for irinotecan and mk-8776
| Article | Year |
|---|---|
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.
Topics: Camptothecin; Cell Cycle Checkpoints; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Gene Expression Regulation, Neoplastic; Half-Life; HCT116 Cells; Humans; Irinotecan; Kinetics; Phosphorylation; Polyribosomes; Protein Biosynthesis; Protein Kinases; Pyrazoles; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |